

Evidence for an Actual Cure of a SHIV-infected Monkey

José M. Martínez-Navío^{1*}, Sebastian P. Fuchs^{1,2*}, Shara N. Pantry¹, Natasha N. Duggan³, William A. Lauer¹, Eva G. Rakasz⁴, Brandon F. Keele⁵, Michel C. Nussenzweig^{6,7}, Jeffrey D. Lifson⁵, Guangping Gao⁸ & Ronald C. Desrosiers^{1*}



¹ Department of Pathology, University of Miami Miller School of Medicine, Miami, FL 33136, USA; ² Institute for Biophysics and Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054 Germany; ³ Department of Molecular Cell and Developmental Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA; ⁴ Wisconsin National Primate Research Center, University of Wisconsin, Madison, WI 53711, USA; ⁵ AIDS and Cancer Virus Program, Los Alamos National Laboratory, Los Alamos, NM 87545, USA; ⁶ Center for Experimental Research, Friedrich-List-Universität, Berlin, Germany; ⁷ Laboratory of Immunology and ⁸ Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10021, USA; ^{*} These authors contributed equally to this work. *Mortar




Abstract

Four rhesus monkeys were infected with SHIV-AD8 for 86 weeks before receiving adeno-associated virus (AAV) vectors expressing *rhusedis* IgG1 versions of anti-HIV monoclonal antibodies 10E8, 3BNC117, and 10-1074 in a therapeutic approach. 10E8 was successfully delivered to none of the four monkeys; 3BNC117 to one of the four monkeys; 10-1074 to three of the four monkeys. SHIV-infected monkey rh2438 maintained serum concentrations of 3BNC117 and 10-1074 of 75 – 150 µg/ml for 17 months after AAV administration. Monkey rh2438 never received antiviral drugs at any time. The viral load set point in rh2438 was 10,000 – 20,000 viral RNA copies per ml of plasma for the prolonged period leading up to the time of AAV inoculation. Following the initial decline in viremia after AAV administration, viral loads remained suppressed to below the limit of detection of 30 RNA copies per ml of plasma for 17 months. During this time rh2438 anti-p27gag antibodies declined more than 10-fold. Attempts to recover SHIV from the peripheral blood of rh2438 were unsuccessful, including *in vitro* cultures of 10⁶ CD8-depleted PBMCs. Two attempts to adoptively transfer infection to naïve recipients using lymph nodes taken from rh2438 failed to transmit the infection. These findings highlight the potential of AAV-mediated antibody expression for impacting HIV-1 infections.

Methods

After 86 weeks of SHIV-AD8 infection, four rhesus macaques were inoculated intramuscularly with three different AAVs coding for three different broadly neutralizing anti-HIV antibodies in a therapeutic approach:




Viral loads were measured by RT-PCR. Antibody and anti-antibody levels were measured by standard ELISA. Adoptive transfer involved surgical removal of lymph nodes from the monkey with undetectable viremia, single cell suspension preparation and inoculation of the cells in two separate naïve recipient animals.

Background

HIV infection can be suppressed with anti-retroviral treatment (ART) but the existence of long-term reservoirs allows the viral load to rebound quickly after ART interruption¹. Attempts to purge these reservoirs *in vivo* have not been successful and viral inducers may have serious undesirable effects^{2,3}. Consequently, there is intense interest at the current time in finding strategies to prevent this rebound, i.e. finding a “functional cure”. Passive transfer of broadly neutralizing antibodies (bNAbs) can prevent infection⁴⁻⁶, and also suppress active infection in humanized mice and macaques⁷⁻¹⁰. Importantly, bNAbs can also suppress HIV emerging from the viral reservoir¹¹ and therefore they could be a good alternative to ART^{12,13}. However, periodic administrations of large amounts of protein would be required for long-term effects, otherwise and similarly to ART, discontinuation of bNAb therapy would result in viral rebound¹². A potential solution for overcoming this, is the use of recombinant adeno-associated virus vectors (AAV)¹³. AAV has an outstanding safety record in clinical trials¹⁴ and, as long as the delivered protein is viewed as self¹⁵, it can result in continuous durable expression of the transgene product for years¹⁶⁻²⁰. The idea is that HIV-infected people could get one shot of AAV making a cocktail of bNAbs and if satisfactory levels of antibody could be maintained *in vivo*, those individuals would remain suppressed for years without having to take ART or receive regular antibody administrations. Our intention is to perform experiments in monkeys that will inform and guide development of this concept for use in people.


Results

1. Antibody and host anti-antibody levels were quantified by ELISA in all four AAV recipients:




Results


2. After AAV administration, animal rh2438 achieved profound and sustained virologic control during the chronic phase of the infection:




3. Monkey rh2438 persistently maintained high concentrations of broadly neutralizing anti-HIV antibodies 3BNC117 and 10-1074 in serum following the AAV administration:




4. Analysis of the viral reservoir in PBMCs isolated from rh2438 revealed a drop in both, viral RNA and viral DNA, after the AAV inoculation:



5. Serum from rh2438 showed a sudden and marked decrease in antibody reactivity to p27/gag and g120/envelope after AAV inoculation:



6. Attempts to recover SHIV from the peripheral blood of rh2438 did not yield any virus. Importantly, lymph node cells from this animal were not able to transmit infection when inoculated in two separate naïve recipient monkeys:



References

- Chen, T.Y. and A.S. Fauci, HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. *AIDS*, 2012, 26(10), p. 1281-8.
- Arch, N.M. et al., Eradicating HIV-1 infection: seeking to cure a persistent pathogen. *Nat Rev Microbiol*, 2014, 12(11), p. 750-64.
- Shan, L. et al., Elimination of HIV-1-specific cytotoxic T lymphocyte facilitates elimination of latent viral reservoir after virus reactivation. *Immunity*, 2012, 36(3), p. 491-501.
- Shaner, K. et al., Passive transfer of neutralizing and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. *J Exp Med*, 2014, 211(10), p. 2061-74.
- Barndekar, V.O. et al., Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. *J Virol*, 2013, 87(11), p. 3860-60.
- Moore, B. et al., Highly potent HIV-specific antibody neutralization *in vitro* translates into effective protection against repeated SHIV challenge *in vivo*. *Proc Natl Acad Sci U S A*, 2012, 109(49), p. 19212-17.
- Klein, F. et al., HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. *Nature*, 2012, 490(7427), p. 119-22.
- Barouch, D.A. et al., Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. *Nature*, 2011, 479(7375), p. 224-8.
- Shaner, M. et al., Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viremia. *Nature*, 2013, 503(7473), p. 277-80.
- Horwitz, J.A. et al., HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drug in humanized mice. *Proc Natl Acad Sci U S A*, 2013, 110(41), p. 16538-43.
- Chen, T.Y. et al., Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. *Proc Natl Acad Sci U S A*, 2014, 111(36), p. 13315-16.
- Hughes, M.D. et al., Broadly neutralizing antibodies and viral inducer decrease reservoir size in HIV-1 latent reservoirs in humanized mice. *Cell*, 2014, 158(5), p. 986-99.
- Durr, C.E. and R. Baruch, Vector antibody gene delivery for the prevention or treatment of HIV infections. *Cell Opin HIV AIDS*, 2013, 10(3), p. 182-7.
- Hughes, M.D. et al., Adeno-associated virus as a platform for gene therapy: discovery, research, and gene therapy success-a personal perspective. *Hum Gene Ther*, 2013, 24(5), p. 257-65.
- Martinez-Navio, J.M. et al., Host-antibody interactions following Adeno-associated Virus-mediated HIV and SHIV in Rhesus Monkeys. *Mol Ther*, 2015.
- Davis, S. and K.J. Baruch, Gene therapy using adeno-associated virus vectors. *Clin Microbiol Rev*, 2002, 15(4), p. 583-93.
- Concannon, T.A., Adeno-associated virus as a delivery vector. *Virus*, 2009, 2(2), p. 4-12.
- McCarty, D.M., Self-complementary AAV vectors: advances and applications. *Mol Ther*, 2009, 18(10), p. 1548-56.
- Schwarz, R.R. and J.S. Chamberlain, Recombinant adenovirus-associated virus transduction and integration. *Mol Ther*, 2009, 16(7), p. 1159-69.
- Mingozzi, F. and K.A. High, Therapeutic *in vivo* gene transfer for genetic disease using AAV: progress and challenges. *Nat Rev Genet*, 2011, 12(5), p. 341-55.

Conclusions

- We have shown evidence for an actual cure of a SHIV-infected monkey during the chronic phase of the infection.
- Long term delivery of potent and broadly neutralizing antibodies with AAV is a very promising approach against HIV.